DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 206307
, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are five patents protecting this drug. Additional details are available on the XTORO profile page.
The generic ingredient in XTORO is finafloxacin. Additional details are available on the finafloxacin profile page.
Summary for NDA: 206307
|Patents:||1|Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Dec 17, 2014||TE:||RLD:||Yes|
|Patent:||6,133,260||Patent Expiration:||Apr 12, 2017||Product Flag?||Y||Substance Flag?||Y||Delist Request?||
|Patent:||6,432,948||Patent Expiration:||Apr 12, 2017||Product Flag?||Y||Substance Flag?||Y||Delist Request?||
|Regulatory Exclusivity Expiration:||Dec 17, 2019
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
Expired Orange Book Patents for NDA: 206307
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.